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Introduction: Hodgkin’s lymphoma is a highly curable disease. Autologous and reduced
intensity allogeneic hematopoietic cell transplantations are alternatives to treat relapsed
patients. Here, we report on the results of one service using these procedures.
Methods: All patients who underwent transplantations in our institution between 1996 and
2014  were retrospectively studied and demographics, toxicities and survival rate were ana-
lyzed.
Results: This study evaluated 24 autologous and ﬁve reduced intensity allogeneic transplan-
tations: the median ages of the patients were 29 and 32 years, respectively. At the time of
autologous transplantation, ten patients were in complete remission, nine had chemosensi-
tive disease but were not in complete remission, three had refractory disease and the status
of  two is unknown. In the allogeneic group, two were in complete remission and three had
chemosensitive disease. The 5-year overall survival after autologous transplantation was
42%  (66% patients were in complete remission, 37% had chemosensitive disease with incom-
plete  remission and 0% had refractory disease) and 1-year overall survival after allogeneic
transplantation was 80%. Transplant-related mortality was 0% in patients conditioned with
the  ifosfamide/carboplatin/etoposide (ICE), carmustine/etoposide/cyclophosphamide (BEC)
and  carmustine/etoposide/cytarabine/melphalan (BEAM) regimens, 37% in patients condi-
tioned with busulfan-based regimens and 20% in allogeneic transplantations.
Conclusions: Hematopoietic cell transplantation for relapsed Hodgkin’s lymphoma is a
potentially curative procedure especially in patients in complete remission at the time of
autologous transplantations, and possibly after allogeneic transplantations. Further studies
are  necessary to clarify the role of allogeneic transplantations in the treatment of relapsed
Hodgkin’s lymphoma.© 2015 Associac¸ão Bra
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odgkin’s Lymphoma (HL) is a highly curable disease with
hemotherapy and radiotherapy.1 However, depending on sev-
ral risk factors and stage at diagnosis,2,3 a group of patients
ill relapse during the follow-up. Several studies have shown
hat in patients with localized disease, depending on the
evel of risk, the probability of relapse varies between 10 and
0% after treatment with the adriamycin, bleomycin, vin-
lastine and dacarbazine regimen (ABVD) and radiotherapy.2
owever, the relapse rate can be as high as 40–50% for
atients with advanced disease.3 Several drugs are under
tudy for the treatment of relapsed/refractory patients but
ntil now, none of them have been able to induce long-term
emission.4 In these cases, only autologous hematopoietic cell
ransplantation (auto HCT) has shown to induce long-term
emission.
Two randomized studies have shown a signiﬁcant bene-
t of freedom from second failure but not on overall survival
OS) when comparing chemotherapy alone with auto HCT.5,6
n the other hand, the role of reduced intensity allogeneic
CT (allo RIC HCT) has been controversial and several small
tudies and case series have suggested a potent graft-versus-
ymphoma (GVL) effect and a lower relapse rate compared to
uto HCT,7 although no direct comparisons between the two
rocedures exist. Initial studies with myeloablative condition-
ng regimens showed high transplant-related mortality (TRM)
nd graft-versus-host disease (GVHD) rates.8,9 More recently,
he use of RIC regimens has been associated with lower TRM,
owever, their role in the treatment of relapsed HL is not very
lear yet, with suggestions for their use in cases of relapse
fter auto HCT, failure to harvest autologous cells or early
elapses after chemotherapy.7 Also, the use of haploidenti-
al donors has preliminary shown interesting results with
xtremely low toxicity and low risk of GVHD, but maintaining
he GVL effect.10
Herein the results of a cohort of patients with
elapsed HL submitted to auto HCT and allo RIC HCT are
eported.
ethods
atients
 retrospective analysis of the HCT database at the Pontif-
cia Universidad Catolica de Chile, Santiago was performed,
hich included patients transplanted between 1996 and 2014.
emographic data, as well as date of diagnosis, date of
ransplant, type of graft and conditioning regimen, age, gen-
er, remission status at transplant, number of CD34+ cells
nfused, time to neutrophil and platelet engraftment, com-
lications, cause of death, time to event (death or relapse)
nd OS (time to last follow-up or death) were obtained. For
atients submitted to allo RIC HCT, the type of GVHD pro-
hylaxis, and grade and time to the diagnosis of GVHD were
lso obtained. This study was approved by the Ethics Com-
ittee and by the Medical Research Center Committee of the
ospital. 1 5;3  7(3):184–189 185
Mobilization  and  leukapheresis
Two methods were used for autologous cell collection:
chemomobilization and chemotherapy followed by ﬁlgrastim
(10 g/kg/day) starting on Day +5 after chemotherapy until the
day of the leukapheresis (usually 10–14 days after chemother-
apy) and ﬁlgrastim (10 g/kg/day) alone for ﬁve days. The
number of CD34+ cells in the peripheral blood was counted
by ﬂow cytometry the day before the programmed collection.
If the quantity was >20 × 106/L, collection was performed to
obtain a minimum of 2 × 106 CD34+ cells/kg. If the CD34+
count was <20 × 106/L, a dose of plerixafor (0.24 mg/kg) was
administered subcutaneously 9–11 h before another collection
to target a minimum of 2 × 106 CD34+ cells/kg, with up to
ﬁve consecutive leukapheresis. For allogeneic collections, ﬁl-
grastim (10 g/kg/day) was administered for ﬁve days before
collection without measuring the CD34+ cells the day before
collection.
Deﬁnitions
The type of response before the transplant was based on
the criteria of Cheson et al. 11,12 depending on the availabil-
ity of positron emission tomography-computed tomography
(PET/CT) and the time of the transplant. The responses were
categorized as complete response (CR), incomplete response
with chemosensitive disease (non-CR CS) and incomplete
response refractory to chemotherapy (non-CR R) according
to the stratiﬁcation proposed by the Center for International
Blood and Marrow Transplant Research (CIBMTR)13 and the
National Marrow Donor Program (NMDP).14
Donor  selection,  conditioning  regimens,
prophylaxis  of  graft-versus-host  disease  and
infectious  diseases,  and  treatment
After the decision to transplant was made, the majority of
patients in second CR (CR2) or non-CR CS underwent auto
HCTs. Patients from whom it was impossible to collect an ade-
quate number of CD34+ cells, non-CR R patients, and those in
third or more  remission with a suitable donor (fully matched
or haploidentical sibling or matched unrelated donor) were
recommended for allo RIC HCTs.
Conditioning regimens for auto HCT between 1996 and
2003 included busulfan/melphalan/thiotepa (BMT) and busul-
fan/etoposide/cyclophosphamide (BuEC); in 2004 the service
started using the ifosfamide/carboplatin/etoposide (ICE),
carmustine/etoposide/cyclophosphamide (BEC) and carmus-
tine/etoposide/cytarabine/melphalan (BEAM) regimens. Allo
RIC regimens included ﬂudarabine/melphalan (FluMel), and
ﬂudarabine/cyclophosphamide/total body irradiation with or
without post-transplant cyclophosphamide (as in the case of
haploidentical transplants).
GVHD prophylaxis was made with cyclosporine/
methotrexate, or tacrolimus/methotrexate/post-transplant
cyclophosphamide (for haploidentical transplants).
Prophylaxis against infectious diseases included levoﬂox-
acin (500 mg  QD) starting on Day -1 until neutrophil recovery
or febrile neutropenia, acyclovir (400 mg  TID) starting on Day
oter.
submitted to allo RIC HCT had a median time to neutrophil
engraftment of 13 days (range: 10–17 days) with 13 days (range,
10–22 days) to platelet engraftment.
Table 2 – Transplant characteristics.
Autologous transplantation
Conditioning regimen
Bu/Mel/Tio 9
Bu/Eto/Cy 3
ICE 7
BEC 4
BEAM 1
CD34 cell dose – ×106/kg (range) 2.87 (1.51–16.9)
Number of collections – n (range) 2 (1–4)
Neutrophil engraftment – days (range) 11 (6–28)
Platelet engraftment – days (range) 12 (8–29)
Allogeneic transplantation186  rev bras hematol hem
-1 until Day +365, ﬂuconazole (200 mg  QD) starting on Day -
1 until Day +100 and sulfametoxazol trimetoprim (QD) three
times per week starting on neutrophil recovery until Day +365.
All the patients were kept in isolation rooms with high-
efﬁciency particulate air ﬁlters and positive pressure during
the neutropenic phase of the transplant. They were given a
neutropenic diet and received ﬁlgrastim (300 g IV) starting
on Day +5 until neutrophil engraftment.
Statistical  analysis
The statistical analysis was performed using GraphPad ver-
sion 6.0f (GraphPad Software, Inc. La Jolla, CA, USA). Variables
are reported as numbers and percentages. OS was measured
from transplantation until death by any cause. Patients alive at
the time of analysis were censored at the last follow-up date.
TRM was deﬁned as death with no evidence of progression or
relapse and was measured from the day of transplantation.
Death after disease progression was treated as a competing
event in the calculation of TRM. Survival curves (OS and TRM)
were obtained using the Kaplan–Meier method and were com-
pared with the Log-Rank Test.
Results
Population  characteristics
Between 1996 and 2014 29 HCT were performed for HL; 24 auto
HCT and ﬁve allo RIC HCT. The median age for the 24 auto
HCT patients, including 13 men  (54%), was 29 years (range:
20–60 years). At the time of the auto HCT, ten patients were in
CR, nine were in non-CR CS, three in non-CR R and the status
of two was unknown. The median age for the allo RIC HCT
patients was 32 years (range: 22–46 years), and all were men;
two of the patients were in CR and three were in non-CR CS
(Table 1).
Table 1 – Patient characteristics.
Autologous Allogeneic
Patients – n 24 5
Age – years (range) 29 (20–60) 32 (22–46)
Gender –
male/female
13/11  5/0
Remission status
CR 10 2
Non-CR, sensitive 9 3
Non-CR, refractory 3 0
Unknown 2 0
Median follow up –
days (range)
493 (9–4822) 364 (40–778)
Cause of death
respiratory failure 8
lymphoma 4
MOD 1
unknown 3
CR: complete response; MOD: multiple organ dysfunction. 2 0 1 5;3  7(3):184–189
Transplant  procedure
Transplant characteristics are shown in Table 2. Of all the
patients submitted to auto HCT, 12 (50%) received condition-
ing regimens based on busulfan. The rest of the patients
(n = 12) were conditioned with the ICE, BEC or BEAM regimens.
Patients submitted to allo RIC HCT were all conditioned with
RIC regimens as mentioned in the Methods section.
The CD34+ cell doses in auto HCT and allo RIC HCT
were 2.87 × 106 cells/kg (range: 1.51–16.9 × 106 cells/kg) and
6.6 × 106 cells/kg (range: 3.5–12 × 106 cells/kg), respectively.
Median number of apheresis required for the minimum CD34+
cell dose was two (range: 1–4) in auto HCT and one in allo RIC
HCT.
The median time to neutrophil engraftment was 11 days
(range: 6–28 days) with 12 days (range: 8–29 days) for platelet
engraftment in patients who underwent auto HCT. PatientsDonor
Sibling 6/6 2
Sibling 3/6 1
Unrelated 8/8 2
Conditioning regimen
Flu/Mel 2
Flu/Cy/TBI 2
Flu/Cy/TBI/Cy 1
CD34 cell dose – ×106/kg (range) 6.6 (3.5–12)
Number of collections – n (range) 1 (1)
Neutrophil engraftment – days (range) 13 (10–17)
Platelet engraftment – days (range) 13 (10–22)
GVHD prevention – n
CS/MTX 4
TAC/MTX 1
GVHD – n (%)
Acute 2 (40%)
chronic 1 (33%)
GVHD: graft vs. host disease; Bu/Mel/Tio: busulfan, melpha-
lan, thiotepa; Bu/Eto/Cy: busulfan, etoposide, cyclophosphamide;
ICE: ifosfamide, carboplatin, etoposide; BEC: carmustin, etopo-
side, cyclophosphamide; BEAM: carmustin, etoposide, cytarabine,
melphalan; Flu/Mel: ﬂudarabine, melphalan; Flu/Cy/TBI: ﬂu-
darabine, cyclophosphamide, total body irradiation; CS/MTX:
cyclosporine, methotrexate; TAC/MTX: tacrolimus, methotrexate,
post-transplant cyclophosphamide.
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Figure 1 – Overall survival after autologous and allogeneic
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Figure 3 – Transplant-related mortality.
Auto: autologous hematopoietic cell transplantation; Allo
RIC: reduced intensity allogeneic hematopoietic cellransplantation.
raft-versus-host  disease
n the allo RIC HCT group, two of ﬁve patients (40%) had Grade
 acute GVHD of the skin. From three evaluable patients, one
ad localized chronic GVHD (33%) of the liver, which was ade-
uately controlled by standard immunosuppression.
urvival
edian follow-up time in patients submitted to auto HCT
as 429 days (range; 9–4837 days). There were 11 deaths due
ainly to respiratory failure and HL relapse (Table 1). The
-year OS and progression free survival were 42% and 33%,
espectively (Figure 1). OS, according to remission status, was
6% in CR patients, 37% in non-CR CS and 0% in non-CR R
isease (p-value = 0.03; Figure 2).Median follow-up time in patients submitted to allo RIC
CT was 364 days (range: 40–778 days). There was one death
hortly after transplant (Table 1). The 1-year OS was 80%
Time after transplant (days)
CR: Complete response; Non-CR CS: Incomplete response with
chemosensitive disease; Non-CR R: Incomplete response
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igure 2 – Overall survival according to remission status in
utologous transplantation.
R: Complete response; Non-CR CS: Incomplete response
ith chemosensitive disease; Non-CR R: Incomplete
esponse refractory to chemotherapy.transplantation.
(Figure 1) and of four evaluable patients, one relapsed (pro-
gression free survival: 75%).
Transplant-related  mortality
Of the patients conditioned with busulfan and submitted to
auto HCT, four (37%) died due to transplant-related complica-
tions (Figure 3). Of the patients who underwent allo RIC HCT,
one out of ﬁve patients (20%) died due to transplant-related
complications (Figure 3)
Discussion
HL is a highly curable disease with chemotherapy and radio-
therapy, but patients who relapse or have refractory disease
are a therapeutic challenge. After relapse, the standard treat-
ment is auto HCT5,6,15,16 with about half of the patients being
cured with this procedure. This beneﬁt has been shown only
in freedom from treatment failure but not in OS. It has been
suggested that this is due to the patients in the chemother-
apy arm, who subsequently received an auto HCT when they
relapsed after chemotherapy. In our cohort, more  than 60% of
the auto HCT patients were living ﬁve years after transplant.
However, the remission status at the time of the transplant is
important since patients not in CR had signiﬁcantly worse OS
than CR patients. Similar data were reported by Lazarus et al.
where patients in CR had an OS close to 80% compared to 60%
in patients with partial response and 40% in those with refrac-
tory disease.17 In a recent publication by Jostling et al., the
authors also showed that the OS was close to 80% in patients
without risk factors compared to 10% in patients with three
risk factors at the time of transplant.18
Another ﬁnding of this study was the signiﬁcantly high
TRM with older conditioning regimens based on busulfan
(37%) compared to more  recent conditioning regimens includ-
ing ICE, BEC and BEAM which, in this series, were not asso-
ciated with TRM. Considering previous reports of secondary
oter.
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cancers with total body irradiation, this procedure is not
included in the preparation for transplant in our service.19 In
our group there was no standard criterion to select a speciﬁc
conditioning regimen, however recently, the BEAM regimen is
being used more  often due to the results of Jostling et al. 18
Allo RIC HCT was performed in the few patients considered
to be at high-risk, and who had failed the CD34+ collection
or for whom bad disease control was anticipated using an
auto HCT.18 Considering the dismal results with myeloabla-
tive regimens mainly related to high TRM,20 only allo RIC
HCT was performed. Although no randomized studies com-
pare these two types of transplants, several case series and
registry analyses suggest that in advanced disease patients
the OS could be over 60% and the TRM lower than 10%.16
Moreover, the evidence suggests that the GVL effect could
be signiﬁcant, especially in patients transplanted early after
relapse.21,22 In the current series, although the number of allo
RIC HCT patients was low (n = 5), TRM was low and 1-year OS
was 80%, which is similar to other studies.23,24 Similarly, the
incidence of acute and chronic GVHD in this population, even
though the number of patients is low, is in agreement with
previous reports. Despite the fact that the results with allo
RIC HCT are encouraging, its speciﬁc role in the management
of relapsed HL is not clear and it is recommended to include
these patients in clinical trials, whenever possible.25 Recently,
a Phase II study suggested that haploidentical donors could
offer better results than matched sibling donors, with very low
TRM and GVHD risk, and without evidence of any loss of the
GVL effect10 thus opening a new alternative for these patients.
The main problems of the current study are its retrospec-
tive nature and the low number of patients. However, this is
the ﬁrst transplant series for HL from Chile and the data is in
line with international series. A previous study by Puga et al.26
reported results on engraftment and mucositis in the ﬁrst ten
auto HCT performed in the public health system, where they
included seven patients with HL with different response rates
before transplant. They did not report on OS or TRM so no
comparisons can be made.
Conclusions
The results with auto HCT in this study are similar to previous
reports, especially emphasizing the high curability in patients
in CR before transplantation. Also, the results with allo RIC
HCT are encouraging regarding OS and TRM and are in line
with international series remembering that the follow-up and
number of patients is still low. Other studies will be necessary
to better establish the role of allo RIC HCT in the treatment of
relapsed HL.
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